-UK cost agency not ready to back Gilead hepatitis C drug
LONDON - Britain's healthcare cost-effectiveness watchdog NICE said on Monday it needed more information about Gilead Sciences' pricey new hepatitis C drug Sovaldi before deciding if it should be used ...